ProPharma Group GmbH was founded on May 9, 2009 and is headquartered in Berlin. The company is a 100-percent subsidiary of ProPharma Group The Netherlands B.V., which prepares the consolidated financial statements for the smallest group. The firm operates in the fields of pharmaceuticals, biotechnology and medical technology and provides services for the development and approval of drugs, medical devices and food products. ProPharma supports products from clinical development to commercialization, ensures regulatory requirements are met and focuses on guaranteeing patient safety. In the 2024 financial year the company employed an average of 88 workers.
Erbringung von Dienstleistungen für Unternehmer oder öffentliche Einrichtungen in der Entwicklung und Zulassung von Arzneimitteln, Medizinprodukten und Nahrungsmitteln.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 121013 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Jason DeGoes | Geschäftsführer(in) | Pawtucket, Rhode Island/Vereinigte Staaten |
| Dawn Sherman | Geschäftsführer(in) | Naples, Florida / Vereinigte Staaten |
| Brian Tuttle | Geschäftsführer(in) | Wilmington, North Carolina / Vereinigte Staaten |
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 121013 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€7.8M2 | €528,433 | €17,553,124 | — |
| 2023 | €13,401,660 | €1,453,052 | €12,153,139 | — |
| 2022 | €15,333,404 | €1,703,700 | €9,250,330 | — |
| 2021 | — | €196,831 | €3,988,915 | — |
| 2020 | — | €809,118 | €1,720,466 | — |
| 2019 | — | €160,443 | €1,387,139 | — |
| 2018 | — | -€294,446 | €1,640,594 | — |
| 2017 | — | -€432,134 | €2,304,168 | — |
| 2016 | — | €38,128 | €3,067,617 | — |
| 2015 | — | €177,636 | €1,732,067 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 121013 (as of 30 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €6,898,718 | 99.2% |
| Depreciation | €55,187 | 0.8% |
